Not applicableStudy completedNCT00536796
What this trial is testing
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
Who this might be right for
HyperlipidemiasAtherosclerosisCoronary Heart Disease+3 more
AstraZeneca 1,096
Showing 20 of 0 results